25.72
price up icon0.47%   0.12
 
loading
前日終値:
$25.60
開ける:
$25.62
24時間の取引高:
29.42M
Relative Volume:
0.78
時価総額:
$145.76B
収益:
$63.63B
当期純損益:
$8.03B
株価収益率:
18.24
EPS:
1.41
ネットキャッシュフロー:
$9.84B
1週間 パフォーマンス:
-3.78%
1か月 パフォーマンス:
+0.74%
6か月 パフォーマンス:
-12.13%
1年 パフォーマンス:
-8.57%
1日の値動き範囲:
Value
$25.50
$25.76
1週間の範囲:
Value
$25.50
$27.24
52週間の値動き範囲:
Value
$24.48
$31.54

Pfizer Inc Stock (PFE) Company Profile

Name
名前
Pfizer Inc
Name
セクター
Healthcare (1171)
Name
電話
(212) 733-2323
Name
住所
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Name
職員
81,000
Name
Twitter
@Pfizer
Name
次回の収益日
2025-02-04
Name
最新のSEC提出書
Name
PFE's Discussions on Twitter

PFE を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
PFE
Pfizer Inc
25.72 145.76B 63.63B 8.03B 9.84B 1.41
Drug Manufacturers - General icon
LLY
Lilly Eli Co
813.48 730.64B 45.04B 10.59B 414.30M 11.71
Drug Manufacturers - General icon
ABBV
Abbvie Inc
211.77 373.85B 56.33B 4.28B 17.83B 2.40
Drug Manufacturers - General icon
JNJ
Johnson Johnson
162.81 344.63B 88.82B 14.07B 18.06B 5.79
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
77.15 342.47B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
MRK
Merck Co Inc
94.57 251.88B 64.17B 17.12B 18.10B 6.73

Pfizer Inc Stock (PFE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-10 再開されました BofA Securities Neutral
2024-11-15 開始されました Wolfe Research Underperform
2024-10-25 再開されました Citigroup Neutral
2024-10-17 開始されました Bernstein Mkt Perform
2024-08-07 アップグレード Daiwa Securities Neutral → Outperform
2024-03-22 ダウングレード Argus Buy → Hold
2024-02-23 開始されました Guggenheim Buy
2024-01-04 ダウングレード TD Cowen Outperform → Market Perform
2023-10-20 再開されました UBS Neutral
2023-10-16 アップグレード Jefferies Hold → Buy
2023-07-17 繰り返されました JP Morgan Neutral
2023-07-14 開始されました HSBC Securities Buy
2023-06-29 ダウングレード Credit Suisse Outperform → Neutral
2023-05-11 ダウングレード Daiwa Securities Outperform → Neutral
2023-03-06 開始されました Jefferies Hold
2023-02-07 アップグレード Daiwa Securities Neutral → Outperform
2023-01-26 ダウングレード UBS Buy → Neutral
2023-01-17 ダウングレード Wells Fargo Overweight → Equal Weight
2023-01-04 ダウングレード BofA Securities Buy → Neutral
2022-12-13 アップグレード Goldman Neutral → Buy
2022-11-18 開始されました Credit Suisse Outperform
2022-05-23 開始されました SVB Leerink Mkt Perform
2022-04-06 再開されました Morgan Stanley Equal-Weight
2022-01-05 アップグレード BofA Securities Neutral → Buy
2022-01-03 繰り返されました Bernstein Mkt Perform
2021-12-20 繰り返されました Cowen Outperform
2021-12-17 開始されました Goldman Neutral
2021-12-13 アップグレード UBS Neutral → Buy
2021-12-09 開始されました Wells Fargo Overweight
2021-11-19 開始されました BMO Capital Markets Outperform
2021-07-27 再開されました Truist Buy
2021-05-06 ダウングレード Mizuho Buy → Neutral
2021-04-07 再開されました RBC Capital Mkts Sector Perform
2021-02-04 アップグレード DZ Bank Hold → Buy
2020-12-16 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-11-19 再開されました Goldman Neutral
2020-11-10 再開されました Bernstein Mkt Perform
2020-10-12 ダウングレード Atlantic Equities Overweight → Neutral
2020-09-29 開始されました Berenberg Hold
2020-06-16 開始されました SVB Leerink Mkt Perform
2020-02-27 開始されました Barclays Equal Weight
2020-02-27 アップグレード Standpoint Research Hold → Buy
2020-02-06 開始されました Mizuho Buy
2020-01-07 開始されました RBC Capital Mkts Outperform
2019-10-17 再開されました BofA/Merrill Neutral
2019-07-30 ダウングレード BofA/Merrill Buy → Neutral
2019-07-30 ダウングレード Morgan Stanley Overweight → Equal-Weight
2019-06-04 再開されました Morgan Stanley Overweight
2019-02-20 再開されました Citigroup Neutral
2019-01-31 アップグレード Argus Hold → Buy
2019-01-31 アップグレード Credit Suisse Neutral → Outperform
2019-01-23 ダウングレード UBS Buy → Neutral
2018-12-11 ダウングレード JP Morgan Overweight → Neutral
2018-11-01 ダウングレード BMO Capital Markets Outperform → Market Perform
すべてを表示

Pfizer Inc (PFE) 最新ニュース

pulisher
04:38 AM

Down 93%, Is It Finally Time to Buy Moderna? - The Motley Fool

04:38 AM
pulisher
Mar 14, 2025

PTAB Explains Ax Of Moderna Vaccine Patents In Pfizer Case - Law360

Mar 14, 2025
pulisher
Mar 14, 2025

10 Most Undervalued S&P 500 Stocks to Buy Now - Insider Monkey

Mar 14, 2025
pulisher
Mar 14, 2025

Sumitomo Pharma, Pfizer Target Two Copies of Orgovyx Cancer Drug - Bloomberg Law

Mar 14, 2025
pulisher
Mar 14, 2025

Pfizer (NYSE:PFE) Faces Shareholder Proposals on Religious Discrimination and Executive Pay Limits - Simply Wall St

Mar 14, 2025
pulisher
Mar 14, 2025

The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J - Zacks Investment Research

Mar 14, 2025
pulisher
Mar 14, 2025

Should You Buy Pfizer Stock At $26? - Forbes

Mar 14, 2025
pulisher
Mar 14, 2025

Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again - Citeline News & Insights

Mar 14, 2025
pulisher
Mar 14, 2025

Basilea Gets Milestone Payment from Pfizer for Antifungal Sales -March 14, 2025 at 03:49 am EDT - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

Pfizer (NYSE:PFE) Shares Unloaded Rep. Julie Johnson - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Guggenheim Reaffirms Buy Rating for Pfizer (NYSE:PFE) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Pfizer's Direct-To-Consumer Model Faces Scrutiny From US Senators (CORRECTED) - Benzinga

Mar 13, 2025
pulisher
Mar 13, 2025

Pfizer Says Chairman & CEO Albert Bourla's 2024 Total Compensation Was $24.6 Mln- SEC Filing - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Pfizer Looks Back at 2024 in the Annual Review - Pfizer

Mar 13, 2025
pulisher
Mar 13, 2025

Form DEF 14A PFIZER INC For: Apr 24 - StreetInsider.com

Mar 13, 2025
pulisher
Mar 13, 2025

White House withdraws vaccine opponent Weldon for CDC director -March 13, 2025 at 12:56 pm EDT - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

May 2nd Options Now Available For Pfizer (PFE) - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Zai Lab says Pfizer drug Tivdak won China review (ZLAB:NASDAQ) - Seeking Alpha

Mar 13, 2025
pulisher
Mar 13, 2025

Womens Health Market Is Booming Worldwide 2025-2032 | Pfizer - openPR

Mar 13, 2025
pulisher
Mar 12, 2025

Pfizer sells park land to Portage for $1, deems property was 'surplus' - wwmtarc

Mar 12, 2025
pulisher
Mar 12, 2025

Is Pfizer Inc. (PFE) the Best Pharma Stock to Buy According to Hedge Funds? - Insider Monkey

Mar 12, 2025
pulisher
Mar 12, 2025

Shareholders Will Be Pleased With The Quality of Pfizer's (NYSE:PFE) Earnings - Yahoo Finance

Mar 12, 2025
pulisher
Mar 12, 2025

Alopecia Areata Market to Expand Significantly by 2032, States DelveInsight Report | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly/ Incyte, Throne Biotech, Legacy Healthcare - Barchart

Mar 12, 2025
pulisher
Mar 12, 2025

Transthyretin Amyloid Cardiomyopathy Treatment Market Is Booming Worldwide 2025-2032: Pfizer Inc., - EIN News

Mar 12, 2025
pulisher
Mar 12, 2025

Breakthroughs in Hyperkalemia DrugsMarket Opportunities - openPR

Mar 12, 2025
pulisher
Mar 12, 2025

A Snapshot Of What Pfizer's Doing With Teleoperated Robots - BioProcess Online

Mar 12, 2025
pulisher
Mar 11, 2025

11 Best Pharma Stocks to Buy According to Hedge Funds - Insider Monkey

Mar 11, 2025
pulisher
Mar 11, 2025

Arvinas/Pfizer’s Vepdegestrant Misses Best Case In Phase III - Citeline News & Insights

Mar 11, 2025
pulisher
Mar 11, 2025

Sector Update: Health Care Stocks Lower in Late Afternoon Trading -March 11, 2025 at 04:05 pm EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Looking At Pfizer's Recent Unusual Options Activity - Benzinga

Mar 11, 2025
pulisher
Mar 11, 2025

Pfizer (NYSE:PFE) Announces Promising Phase 3 Results For Breast Cancer Therapy Vepdegestrant - Simply Wall St

Mar 11, 2025
pulisher
Mar 11, 2025

Pfizer stock, Arvinas stock slip on breast cancer data (PFE:NYSE) - Seeking Alpha

Mar 11, 2025
pulisher
Mar 11, 2025

Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial - Benzinga

Mar 11, 2025
pulisher
Mar 11, 2025

Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients - Yahoo Finance

Mar 11, 2025
pulisher
Mar 11, 2025

Arvinas shares tumble as breast cancer drug with Pfizer shows mixed results - Reuters.com

Mar 11, 2025
pulisher
Mar 11, 2025

mRNA Cancer Therapeutics Patent Landscape Report and - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Injectable Drugs Market Detailed In New Research Report 2025 | Pfizer Inc., Teva Pharmaceutical Industries - EIN News

Mar 11, 2025
pulisher
Mar 11, 2025

Arvinas and Pfizer Announce Positive Phase 3 Trial Results - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Pfizer: Undervalued Safe Haven In Risk-Off Market​ (NYSE:PFE) - Seeking Alpha

Mar 11, 2025
pulisher
Mar 11, 2025

Pfizer's new drug data in breast cancer draws muted response - pharmaphorum

Mar 11, 2025
pulisher
Mar 11, 2025

Pfizer (PFE) Breast Cancer Drug Vepdegestrant Posts Mixed Results in Key Trial - Bloomberg

Mar 11, 2025
pulisher
Mar 11, 2025

Pfizer, Arvinas post mixed late-stage breast cancer data for closely watched PROTAC drug - PharmaLive

Mar 11, 2025
pulisher
Mar 11, 2025

Pfizer: encouraging data in breast cancer -March 11, 2025 at 08:04 am EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Pfizer's breast cancer drug Vepdegestrant posts mixed results in key trial - Business Standard

Mar 11, 2025
pulisher
Mar 11, 2025

Atrial Fibrillation Market to Witness Remarkable Growth with Pfizer Inc., Boehringer Ingelheim GmbH - openPR

Mar 11, 2025
pulisher
Mar 11, 2025

Migraine Therapeutic Market Is Booming Worldwide 2025-2032 | - openPR

Mar 11, 2025
pulisher
Mar 11, 2025

Arvinas, Pfizer Report Positive Topline Data From Phase 3 VERITAC-2 Study - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Arvinas-Pfizer's breast cancer treatment meets main goal in late-stage study -March 11, 2025 at 06:52 am EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Arvinas And Pfizer Announce Positive Topline Results From Phase 3 Veritac-2 Clinical Trial - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

First-Ever PROTAC Cancer Drug Hits Major Trial Milestone: What This Means - StockTitan

Mar 11, 2025

Pfizer Inc (PFE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general SNY
$57.75
price up icon 0.00%
$111.44
price down icon 1.69%
$313.71
price up icon 0.34%
drug_manufacturers_general NVS
$109.06
price down icon 0.05%
drug_manufacturers_general MRK
$94.57
price down icon 0.15%
大文字化:     |  ボリューム (24 時間):